EUCTR2010-018481-22-NL进行中（未招募）1 期
A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens of inhaled indacaterol maleate in patients with persistent asthma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female adult patients aged 18 years or above who have signed an Informed Consent Form prior to initiation of any study-related procedure, including any adjustments to asthma medication prior to the first study visit.
- •2. Patients with asthma, diagnosed according to GINA guidelines 2008 and who additionally meet the following criteria:
- •Patients receiving daily treatment with inhaled corticosteroid up to the maximum dose per day indicated in the package leaflet, in a stable regimen for the month prior to first study visit.
- •Patients with an FEV1 at screening of =50% and =90% of the predicted normal value for the patient. This criterion for FEV1 will have to be demonstrated after a washout period of at least 6 hours during which no short acting ß2-agonist has been inhaled, and a minimum of 48 hours for a long acting ß2-agonist and 7 days for tiotropium.
- •Patients who demonstrate an increase of =12% and =200 mL in FEV1 over their pre-bronchodilator value within 30 minutes after inhaling a total of 400 µg/360 µg of salbutamol/albuterol MDI (or equivalent dose of DPI) (the reversibility test). Reversibility will have to be demonstrated after an appropriate washout period as described above. The administration of salbutamol/albuterol for the reversibility test is to be within 30 minutes after pre bronchodilator spirometry. Reversibility has to be demonstrated at screening or between screening and pre-dose Day 1, in order for patients to be included in the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Patients who have a smoking history of greater than 10 pack years, (defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked). Current smokers who smoke greater than 10 cigarettes per day. Smokers should maintain their usual smoking habits throughout the course of the study.
- •2. Patients who have had previous intubation for a severe asthma attack/exacerbation.
- •3. Patients who have had a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to the first study visit.
- •4. Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to the first study visit or any time between the first study visit and pre-dose Day 1.
- •5. Patients who have had a lower respiratory tract infection within 6 weeks prior to the first study visit or any time between the first study visit and pre-dose Day 1.
- •6. Patients with seasonal allergy whose asthma is likely to deteriorate during the study period.
- •7. Patients who require the use of =8 inhalations per day of the short-acting ß2-agonist (100 µg/90 µg salbutamol/albuterol MDI or equivalent dose of DPI) on any 2 consecutive days from screening to randomization.
- •8. Patients diagnosed with COPD as defined by the (GOLD Guidelines, 2009).
- •9. Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed by chest X-ray to be no longer active) or clinically significant bronchiectasis.
- •10. Any patient with lung cancer or a history of lung cancer.
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotideIrritable Bowel SyndromMedDRA version: 9.1Level: PTClassification code 10023003Term: Irritable bowel syndromeEUCTR2007-004994-25-GBovartis Pharma Services AG46
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAIPreviously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) who have low-intermediate, high-intermediate, or high-risk disease according to the IPI score and patients with bulky tumor (largest diameter = 7.5 cm) regardless of disease risk according to the IPI.MedDRA version: 8.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2006-005520-16-HUF. Hoffmann-La Roche Ltd1,060
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients = 70 years (drug-naive or inadequately controlled on oral agents).EUCTR2010-022658-18-DEovartis Pharma Services AG280
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure.Type 2 DiabetesEUCTR2008-005012-41-CZovartis Pharma Services AG246
进行中（未招募）
不适用
Efficacy and safety of iron chelation therapy with deferasirox compared toplacebo in patients with myelodysplastic syndromes and transfusional ironoverloadEUCTR2009-012418-38-DKovartis Pharma Services AG210